KR20180050744A - 신생물성 세포를 비-신생물성 세포로 전환시키기 위한 약제학적 회합물 및 이것의 용도 - Google Patents

신생물성 세포를 비-신생물성 세포로 전환시키기 위한 약제학적 회합물 및 이것의 용도 Download PDF

Info

Publication number
KR20180050744A
KR20180050744A KR1020187010231A KR20187010231A KR20180050744A KR 20180050744 A KR20180050744 A KR 20180050744A KR 1020187010231 A KR1020187010231 A KR 1020187010231A KR 20187010231 A KR20187010231 A KR 20187010231A KR 20180050744 A KR20180050744 A KR 20180050744A
Authority
KR
South Korea
Prior art keywords
spis
eqlsn
ykqye
eplt
peptide
Prior art date
Application number
KR1020187010231A
Other languages
English (en)
Korean (ko)
Inventor
오마르 에프. 주아니
베로니카 고체바
Original Assignee
히스티드 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 히스티드 아게 filed Critical 히스티드 아게
Publication of KR20180050744A publication Critical patent/KR20180050744A/ko

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18Growth factors; Growth regulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • A61K31/7105Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05Dipeptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07Tetrapeptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08Peptides having 5 to 11 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10Peptides having 12 to 20 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/14Type of nucleic acid interfering N.A.
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/50Physical structure
    • C12N2310/53Physical structure partially self-complementary or closed
    • C12N2310/531Stem-loop; Hairpin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020187010231A 2015-09-17 2016-09-15 신생물성 세포를 비-신생물성 세포로 전환시키기 위한 약제학적 회합물 및 이것의 용도 KR20180050744A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562219728P 2015-09-17 2015-09-17
US62/219,728 2015-09-17
PCT/EP2016/071794 WO2017046227A2 (en) 2015-09-17 2016-09-15 Pharmaceutical association for converting a neoplastic cell into a non-neoplastic cell and uses thereof.

Publications (1)

Publication Number Publication Date
KR20180050744A true KR20180050744A (ko) 2018-05-23

Family

ID=56936411

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020187010231A KR20180050744A (ko) 2015-09-17 2016-09-15 신생물성 세포를 비-신생물성 세포로 전환시키기 위한 약제학적 회합물 및 이것의 용도

Country Status (17)

Country Link
US (1) US20190290729A1 (da)
EP (3) EP3349776B1 (da)
JP (2) JP7236134B2 (da)
KR (1) KR20180050744A (da)
CN (1) CN109715190A (da)
AU (1) AU2016323407A1 (da)
CA (1) CA2998297A1 (da)
DK (1) DK3349776T3 (da)
ES (1) ES2862103T3 (da)
HR (1) HRP20210441T1 (da)
HU (1) HUE053697T2 (da)
IL (2) IL299622A (da)
LT (1) LT3349776T (da)
PL (1) PL3349776T3 (da)
SG (1) SG10201913366QA (da)
SI (1) SI3349776T1 (da)
WO (1) WO2017046227A2 (da)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109311956A (zh) 2015-08-25 2019-02-05 伊斯迪德股份公司 诱导组织形成的化合物及其应用
CA2998455A1 (en) * 2015-09-17 2017-03-23 Histide Ag Pharmaceutical association for converting a neoplastic cell into a non-neoplastic cell and uses thereof
JP2020529472A (ja) 2017-07-28 2020-10-08 サークル ファーマ,インコーポレイティド ペプチド化合物の環化放出関連する出願の相互参照
CN116204770B (zh) * 2022-12-12 2023-10-13 中国公路工程咨询集团有限公司 一种用于桥梁健康监测数据异常检测的训练方法及装置

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
US20030185792A1 (en) * 1996-01-22 2003-10-02 Curis, Inc. Morphogen analogs of bone morphogenic proteins
US5846536A (en) * 1996-10-04 1998-12-08 The Regents Of The University Of California Restoration of normal phenotype in cancer cells
DE19748688C2 (de) * 1997-04-22 2001-09-06 Hans Georg Graeber Membransystem zur gesteuerten Geweberegeneration bei Erkrankungen des Zahnhalteapparates
US20040023322A1 (en) * 2002-08-01 2004-02-05 Goodheart Clyde R. Method of producing non-recombinant BMP-2 and use thereof
WO2005030933A2 (en) * 2003-09-24 2005-04-07 Genera Doo Bone morphogenetic protein (bmp)-7 based diagnosis and treatment of cancer
US7528105B1 (en) * 2004-02-10 2009-05-05 Biosurface Engineering Technologies Heterodimeric chain synthetic heparin-binding growth factor analogs
CA2595902C (en) * 2005-01-24 2017-08-22 Pepscan Systems B.V. Binding compounds, immunogenic compounds and peptidomimetics of the beta-3 hairpin loop of cystine-knot growth factors
ES2710601T3 (es) * 2005-07-19 2019-04-26 Stemgen S P A Inhibición del potencial tumorigénico de células madre tumorales por LIF
WO2007114851A1 (en) * 2006-04-04 2007-10-11 The Board Of Trustees Of The University Of Illinois Methods and compositions to induce cell death of invasive tumors
US7998740B2 (en) * 2006-07-18 2011-08-16 Robert Sackstein Cytokine induction of selectin ligands on cells
GB0615129D0 (en) * 2006-07-29 2006-09-06 Univ Cardiff Anti-cancer activity of BMP-9 and BMP-10 and their use in cancer therapies
KR100894265B1 (ko) * 2007-06-05 2009-04-21 재단법인서울대학교산학협력재단 골형성 촉진 펩타이드를 함유하는 주입형 골재생재
CA2694644A1 (en) * 2007-07-27 2009-02-05 Vanitha Ramakrishnan Pharmaceutical combinations
CN103561761A (zh) * 2011-03-23 2014-02-05 加利福尼亚大学董事会 用于使用抗-整合素改善抗血管生成疗法的方法和组合物
SG11201508681QA (en) * 2013-05-06 2015-11-27 Scholar Rock Inc Compositions and methods for growth factor modulation

Also Published As

Publication number Publication date
AU2016323407A1 (en) 2018-04-19
ES2862103T3 (es) 2021-10-07
LT3349776T (lt) 2021-03-25
SI3349776T1 (sl) 2021-04-30
PL3349776T3 (pl) 2021-08-02
EP3349776A2 (en) 2018-07-25
IL258131A (en) 2018-05-31
HRP20210441T1 (hr) 2021-04-30
WO2017046227A2 (en) 2017-03-23
HUE053697T2 (hu) 2021-07-28
JP2018536623A (ja) 2018-12-13
EP3906932A3 (en) 2021-12-01
IL258131B2 (en) 2023-06-01
SG10201913366QA (en) 2020-02-27
WO2017046227A3 (en) 2017-06-29
IL299622A (en) 2023-03-01
JP7236134B2 (ja) 2023-03-09
CA2998297A1 (en) 2017-03-23
EP3875102A1 (en) 2021-09-08
EP3349776B1 (en) 2020-12-30
JP2023027372A (ja) 2023-03-01
US20190290729A1 (en) 2019-09-26
EP3906932A2 (en) 2021-11-10
DK3349776T3 (da) 2021-03-22
CN109715190A (zh) 2019-05-03

Similar Documents

Publication Publication Date Title
JP6890835B2 (ja) 腫瘍細胞を非腫瘍細胞に変換するための医薬的連合体及びその使用
JP7261499B2 (ja) 腫瘍細胞を非腫瘍細胞に変換するための医薬的連合体及びその使用
JP2023027372A (ja) 腫瘍細胞を非腫瘍細胞に変換するための医薬的連合体及びその使用
EP3349778B1 (en) Pharmaceutical association of growth factor receptor agonist and adhesion protein inhibitor for converting a neoplastic cell into a non-neoplastic cell and uses thereof
WO2017046229A1 (en) Pharmaceutical association of growth factor receptor agonist and adhesion protein inhibitor for converting a neoplastic cell into a non-neoplastic cell and uses thereof

Legal Events

Date Code Title Description
E902 Notification of reason for refusal
E601 Decision to refuse application